AMENDMENTS TO THE CLAIMS

1. (Original) A composition comprising an immune effector cell and a cell penetrating peptide, wherein said cell penetrating peptide is associated with an antigen.

2. (Original) The composition of claim 1, wherein the antigen is a tumor rejection antigen or tumor associated antigen.

3. (Original) The composition of claim 1, wherein the antigen is a molecule comprising multiple T-cell peptides.

4. (Original) The composition of claim 3, wherein the multiple T-cell peptides are from either the same tumor antigen or different tumor antigens.

5. (Original) The composition of claim 1, wherein the antigen comprises at least one MHC class I-restricted peptide, at least one MHC class II-restricted peptide, or at least one MHC class I-restricted peptide and at least one MHC class II-restricted peptide.

6. (Original) The composition of claim 1, wherein the immune effector cell is a mature dendritic cell, a B cell, a macrophage, or a fibroblast.

7. (Original) The composition of claim 1, wherein the immune effector cell is a mature dendritic cell or a B cell.

8. (Original) The composition of claim 1, wherein the immune effector cell is a mature dendritic cell.

9. (Original) The composition of claim 1, wherein the antigen is a tumor antigen.

10. (Original) The composition of claim 9, wherein the tumor antigen is a peptide.

11. (Original) The composition of claim 9, wherein the tumor antigen is TRP2.

12. (Original) The composition of claim 9, wherein the tumor antigen is one from Table 1, Table 2, Table 3, Table 4, or Table 5.

13. (Original) The composition of claim 1, wherein the cell penetrating peptide is CPP1, ANTP, Signal-peptide I, Signal-peptide II, PRES, Transportan, Amphiphilic model peptide, HSV VP22, peptide carrier, or CL22.

14. (Original) The composition of claim 1, wherein the cell penetrating peptide is CPP1.

15. (Original) The composition of claim 1, wherein the association of the cell penetration peptide with the antigen is a covalent bond.

16. (Original) The composition of claim 1, wherein the antigen is housed within a vesicle in said immune system cell.

17. (Original) The composition of claim 16, wherein the vesicle is an endosome.

18. (Cancel)

19. (Original) A vaccine comprising:

an immune effector cell and a cell penetrating peptide, wherein said cell penetrating peptide is associated with an antigen; and

a pharmaceutically acceptable carrier.

20. (Original) The vaccine of claim 19, wherein the immune effector cell is a mature dendritic cell, a B cell, a macrophage, or a fibroblast.

21. (Original) The vaccine of claim 19, wherein the immune effector cell is a mature dendritic cell or a B cell.

22. (Original) The vaccine of claim 19, wherein the immune effector cell is a mature dendritic cell.

23.-46. (Cancel)